Recent News

• 06.11.2025 - Ensysce Biosciences Announces Speakers for Major Symposium at PAINWeek 2025
• 06.04.2025 - Ensysce Biosciences Awarded $5.3 Million in Continued NIDA Support to Advance Breakthrough Opioid Overdose Protection
• 05.13.2025 - Ensysce Biosciences Reports First Quarter 2025 Financial Results
• 05.12.2025 - Ensysce Biosciences Bolsters Management Team with Regulatory Expert
• 04.24.2025 - Ensysce Biosciences, Inc. Announces Closing of Exercise of Warrants for $2.2 Million Gross Proceeds

Recent Filings

• 06.05.2025 - 8-K Current report
• 05.15.2025 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 05.13.2025 - 8-K Current report
• 05.13.2025 - EX-99.1 EX-99.1
• 05.13.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 05.12.2025 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 05.09.2025 - EFFECT Notice of Effectiveness
• 05.09.2025 - UPLOAD SEC-generated letter
• 05.09.2025 - CORRESP Correspondence
• 05.02.2025 - S-8 Securities to be offered to employees in employee benefit plans